Skip to content
DataLookout
Menu

ENI-SPIRE-2NCT07889648

A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change From Baseline to Week 72 in Glycosylated Hemoglobin (HbA1c, %)
Timeframe: Baseline through Week 72

Secondary (24)

Percentage of Participants Achieving HbA1c of ≤6.5% at Week 72
Percentage of Participants Achieving HbA1c of <5.7% at Week 72
Change From Baseline to Week 72 in Fasting Glucose
Percent Change From Baseline to Week 72 in Body Weight
Percentage of Participants Achieving HbA1c of <7% at Week 72
Show 19 moreShow less
Change From Baseline to Week 72 in 7-Point Self-Monitoring Blood Glucose (SMBG) Profiles
Percentage of Participants Achieving HbA1c of <7% at Week 72 Without Clinically Significant, Documented Symptomatic Hypoglycemia, or Severe Hypoglycemia
Percentage of Participants Achieving HbA1c of <6.5% at Week 72 Without Clinically Significant, Documented Symptomatic Hypoglycemia, or Severe Hypoglycemia
Percentage of Participants Achieving HbA1c of <5.7% at Week 72 Without Clinically Significant, Documented Symptomatic Hypoglycemia, or Severe Hypoglycemia
Percentage of Participants Achieving Weight Loss of ≥5% at Week 72
Percentage of Participants Achieving Weight Loss of ≥10% at Week 72
Percentage of Participants Achieving Weight Loss of ≥15% at Week 72
Change From Baseline to Week 72 in Waist Circumference
Change From Baseline to Week 72 in Waist-to-Height Ratio
Percentage of Participants Achieving HbA1c of ≤6.5% and Weight Loss of ≥10% at Week 72
Change From Baseline to Week 72 in Total Cholesterol
Change from Baseline to Week 72 in Triglycerides
Change from Baseline to Week 72 in Low-Density Lipoprotein Cholesterol (LDL-C)
Change from Baseline to Week 72 in High-Density Lipoprotein Cholesterol (HDL-C)
Change From Baseline to Week 72 in Systolic Blood Pressure
Change From Baseline to Week 72 in Diastolic Blood Pressure
Change From Baseline to Week 72 in Urine Albumin to Creatinine Ratio (UACR)
Change From Baseline to Week 72 in High-Sensitivity C-Reactive Protein (hsCRP)
Incidence and Severity of Adverse Events

Arms and interventions

Arm 1: TirzepatideActive comparator

Participants will receive tirzepatide.

Arm 2: EnicepatideExperimental

Participants will receive enicepatide.

Combination products: Enicepatide, Tirzepatide